Disufenton sodium

Disufenton sodium
Systematic (IUPAC) name
Disodium 4-[(Z)-(tert-butyl-oxidoazaniumylidene)methyl]benzene-1,3-disulfonate
Clinical data
Identifiers
 Yes
None
PubChem CID 6440181
UNII 7M1J3HN9VO 
KEGG D03875 Yes
ChEMBL CHEMBL1627056 
Chemical data
Formula C11H13NNa2O7S2
381.33 g/mol
  (what is this?)  (verify)

Disufenton sodium (NXY-059, Cerovive) is the disulfonyl derivative of the neuroprotective spin trap phenylbutylnitrone or "PBN". It was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial[1][2] called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance".[1] AstraZeneca then terminated the development programme.[3] PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH ( AKA, NtBHA ) and its parent spin-trap MNP.

References

  1. ↑ 1.0 1.1 Lees, Kennedy R.; Zivin, Justin A.; Ashwood, Tim; Davalos, Antonio; Davis, Stephen M.; Diener, Hans-Christoph; Grotta, James; Lyden, Patrick et al. (2006). "NXY-059 for Acute Ischemic Stroke". New England Journal of Medicine 354 (6): 588–600. doi:10.1056/NEJMoa052980. PMID 16467546.
  2. ↑ Lees, KR; Davalos, A; Davis, SM; Diener, HC; Grotta, J; Lyden, P; Shuaib, A; Ashwood, T et al. (2006). "Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial". Stroke; a journal of cerebral circulation 37 (12): 2970–8. doi:10.1161/01.STR.0000249410.91473.44. PMID 17068304.
  3. ↑ Renovis: Press Release

External links